ᴴ : Modifier letter H is used in the Uralic Phonetic Alphabet
ₕ : Subscript small h was used in the Uralic Phonetic Alphabet prior to its formal standardization in 1902
ʰ : Modifier letter small h is used in Indo-European studies
ʮ and ʯ : Turned H with fishhook and turned H with fishhook and tail are used in Sino-Tibetanist linguistics
Ƕ ƕ : Latin letter hwair, derived from a ligature of the digraph hv, and used to transliterate the Gothic letter 𐍈 (which represented the sound [hʷ])
Ⱶ ⱶ : Claudian letters
Ꟶ ꟶ : Reversed half h used in Roman inscriptions from the Roman provinces of Gaul

Ancestors, siblings, and descendants in other alphabets
𐤇 : Semitic letter Heth, from which the following symbols derive
Η η : Greek letter Eta, from which the following symbols derive
𐌇 : Old Italic H, the ancestor of modern Latin H
ᚺ, ᚻ : Runic letter haglaz, which is probably a descendant of Old Italic H
Һ һ : Cyrillic letter Shha, which derives from Latin H
И и : Cyrillic letter И, which derives from the Greek letter Eta
𐌷 : Gothic letter haalArmenian letter ho (Հ)

Derived signs, symbols, and abbreviations
h : Planck constant
ℏ : reduced Planck constant

  
    
      
        
          H
        
      
    
    {\displaystyle \mathbb {H} }
   : Blackboard bold capital H used in quaternion notation

Computing codes
1 and all encodings based on ASCII, including the DOS, Windows, ISO-8859, and Macintosh families of encodings.
Insulin glulisine is a rapid-acting modified form of medical insulin that differs from human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine in position B29 is replaced by glutamic acid. It was developed by Sanofi-Aventis and approved for marketing by the FDA in 2004; it is sold under the trade name Apidra. When injected subcutaneously, it appears in the blood earlier than human insulin. When used as a meal time insulin, the dose is to be administered within 15 minutes before or 20 minutes after starting a meal. Intravenous injections may also be used for extreme hyperglycemia, but must be performed under the supervision of a medical professional.The most common side effects include hypoglycaemia (low blood glucose levels). Medical uses
Insulin glulisine is indicated for the treatment of diabetes mellitus. References
External links
"Insulin glulisine". Drug Information Portal. U.S. National Library of Medicine.